-
Product Insights
Drug Hypersensitivity Reactions Disease - Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Drug Hypersensitivity Reactions Global Clinical Trials Review, H1, 2019" provides an overview of Drug Hypersensitivity Reactions clinical trials scenario. This report provides top line data relating to the clinical trials on Drug Hypersensitivity Reactions. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Allergic Diseases - Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, With Strong Presence of Cytokine Mediators Among First-In-Class Products
An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening. Despite this high disease...
-
Sector Analysis
Systemic Lupus Erythematosus - Programs Targeting Cytokine and Growth Factor Signaling Dominate First-In-Class Pipeline
Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The etiology of SLE is not completely understood, but is thought to be the result of genetic/epigenetic abnormalities, and hormonal and environmental factors. In general, autoimmunity is the result of inadequate...
-
Product Insights
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Disease - Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers...
-
Product Insights
Chronic Inflammation Disease - Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Chronic Inflammation Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Inflammation clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Inflammation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Churg-Strauss Syndrome Disease - Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Churg-Strauss Syndrome Global Clinical Trials Review, H1, 2019" provides an overview of Churg-Strauss Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Churg-Strauss Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Corneal Graft Rejection Disease - Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Corneal Graft Rejection Global Clinical Trials Review, H1, 2019" provides an overview of Corneal Graft Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Corneal Graft Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Myasthenia Gravis - Epidemiology Forecast to 2028
Myasthenia gravis (MG) is the most common neuromuscular junction disorder, and is characterized by a fluctuating degree and variable combination of weakness in ocular, bulbar, limb, and respiratory muscles (Lai and Tseng, 2010). In this disease, receptors for acetylcholine at the neuromuscular junction are blocked, altered, or destroyed by the antibodies (immune proteins), which prevent the muscle from contracting. In some cases, antibodies to other proteins, such as the muscle-specific receptor tyrosine kinase (MuSK) protein, can also lead to impaired...
-
Sector Analysis
Axial Spondyloarthritis - Epidemiology Forecast to 2028
Axial spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Based on sacroiliac changes on conventional radiographs, AxSpA is classified into radiographic (r-AxSpA) or nonradiographic (nr-AxSpA) depending on the presence or absence of radiographic changes at the sacroiliac joints. Patients traditionally classified as ankylosing spondylitis (AS) would be considered as r-AxSpA. Some of nr-AxSpA progress to AS and some do not (Sieper...
-
Sector Analysis
Axial Spondyloarthritis - Epidemiology Forecast in Asia-Pacific Markets to 2028
Axial spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Based on sacroiliac changes on conventional radiographs, AxSpA is classified into radiographic (r-AxSpA) or nonradiographic (nr-AxSpA) depending on the presence or absence of radiographic changes at the sacroiliac joints. Patients traditionally classified as ankylosing spondylitis (AS) would be considered as r-AxSpA. Some of nr-AxSpA progress to AS and some do not (Sieper...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.